Patent US5489435A successfully refreshed from Google Patents.
US5489435A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Composition for treatment of abnormal conditions of the epithelium of bodily orifices
Assignee: Micropure Inc
•
Filing: 1993-07-06
•
Granted: 1996-02-06
•
Expires: 2013-07-06
Abstract
Abstract A stable solution, cream, salve, or spray composition containing activated stabilized chlorine dioxide and phosphates, such as disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, and sodium monofluorophosphate, is disclosed for the prevention and treatment of abnormal conditions of the epithelium of bodily orifices. Examples of such abnormal conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices include bacterial infections, such as Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis, and fungal infections, such as Candida, and leukoplakia. The preferred concentration ranges are between about 0.005%-2.0% chlorine dioxide, and between about 0.02%-3.0% phosphate. The phosphate compound retards escape of chlorine dioxide in the pH range of 6.0 to 7.4, at which pH stabilized chlorine dioxide becomes activated and releases sufficient chlorine dioxide to reduce motility and become lethal to the involved micro-organisms.
Inventors
- 👤 Perry A. Ratcliff
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 06:51
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/02; A61K33/00; A61K33/40; A61K33/42; A61K8/00; A61K8/18; A61K8/19; A61K8/20; A61K8/22; A61K8/24; A61K9/00; A61K9/0012; A61K9/0014; A61Q; A61Q11/00; A61Q15/00; Y; Y10; Y10S; Y10S424/00; Y10S424/15
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
160 words
A composition for preventing and treating conditions of the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices, brought about by the occurrence of any of fungal and bacterial infections, leukoplakia, penetration of bacterial toxins, invasion of antigenic substances and microbiota, living unicellular orctanisms, vaginitis, endometriosis, Porphyromonas gingivalis, Actinobactillus actinomycetumcomitans, Pseudomonades, Candida species and leukoplakia vulvae, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains stabilized chlorine dioxide in a concentration in the range of 0.005%-2.0% and a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate, wherein the concentration of said phosphate compound is in a range of between about 0.02%-3.0% to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 2
Dependent Claim
160 words
A composition for preventing and treating conditions of the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices, brought about by the occurrence of any of fungal and bacterial infections, leukoplakia, penetration of bacterial toxins, invasion of antigenic substances and microbiota, living unicellular orctanisms, vaginitis, endometriosis, Porphyromonas gingivalis, Actinobactillus actinomycetumcomitans, Pseudomonades, Candida species and leukoplakia vulvae, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains stabilized chlorine dioxide in a concentration in the range of 0.005%-2.0% and a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate, wherein the concentration of said phosphate compound is in a range of between about 0.02%-3.0% to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 3
Dependent Claim
147 words
A composition for preventing and treating conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices, brought about by the occurrence of any of fungal and bacterial infections, leukoplakia, penetration of bacterial toxins, invasion of antigenic substances and microbiota, living unicellular organisms, vaginitis, endometriosis, Porphyromonas gingivalis, Actinobactillus actinomycetumcomitans, Pseudomonades, Candida species and leukoplakia vulvae, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains stabilized chlorine dioxide in a concentration in the range of 0.005%-2.0% and a phosphate compound comprising trisodium phosphate, wherein the concentration of said phosphate compound is in a range of between about 0.02%-3.0% to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 4
Dependent Claim
147 words
A composition for preventing and treating conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices, brought about by the occurrence of any of fungal and bacterial infections, leukoplakia, penetration of bacterial toxins, invasion of antigenic substances and microbiota, living unicellular organisms, vaginitis, endometriosis, Porphyromonas gingivalis, Actinobactillus actinomycetumcomitans, Pseudomonades, Candida species and leukoplakia vulvae, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains stabilized chlorine dioxide in a concentration in the range of 0.005%-2.0% and a phosphate compound comprising trisodium phosphate, wherein the concentration of said phosphate compound is in a range of between about 0.02%-3.0% to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 5
Dependent Claim
15 words
The composition as set forth in claim 1, wherein the phosphate compound is sodium monofluorophosphate.
Claim 6
Dependent Claim
27 words
The composition as set forth in claim 1, wherein the concentration of stabilized chlorine dioxide is approximately 0.2% and the concentration of phosphate compound is approximately 1.0%.
Claim 7
Dependent Claim
144 words
A composition for preventing and treating conditions of the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices, brought about by the occurence of any of fungal and bacterial infections, leukoplakia, penetration of bacterial toxins, invasion of antigenic substances and microbiota, living unicellular organisms, vaginitis, endometriosis, Porphyromonas gingivalis, Actinobactillus actinomycetumcomitans, Pseudonionades, Candida species and leukoplakia vulvae, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains at least 0.1% stabilized chlorine dioxide and at least 0.05% of a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 8
Dependent Claim
144 words
A composition for preventing and treating conditions of the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices, brought about by the occurence of any of fungal and bacterial infections, leukoplakia, penetration of bacterial toxins, invasion of antigenic substances and microbiota, living unicellular organisms, vaginitis, endometriosis, Porphyromonas gingivalis, Actinobactillus actinomycetumcomitans, Pseudonionades, Candida species and leukoplakia vulvae, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains at least 0.1% stabilized chlorine dioxide and at least 0.05% of a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 9
Dependent Claim
131 words
A composition for preventing and treating conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices, brought about by the occurrence of any of fungal and bacterial infections, leukoplakia, penetration of bacterial toxins, invasion of antigenic substances and microbiota, living unicellular organisms, vaginitis, endometriosis, Porphyromonas gingivalis, Actinobactillus actinomycetumcomitans, Pseudomonades, Candida species and leukoplakia vulvae, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains at least 0.1% stabilized chlorine dioxide and at least 0.05% of a phosphate compound comprising trisodium phosphate to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 10
Dependent Claim
131 words
A composition for preventing and treating conditions of the epithelium of the rectal, vaginal, urethral, oral, nasal, ocular, and auditory canal orifices, brought about by the occurrence of any of fungal and bacterial infections, leukoplakia, penetration of bacterial toxins, invasion of antigenic substances and microbiota, living unicellular organisms, vaginitis, endometriosis, Porphyromonas gingivalis, Actinobactillus actinomycetumcomitans, Pseudomonades, Candida species and leukoplakia vulvae, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains at least 0.1% stabilized chlorine dioxide and at least 0.05% of a phosphate compound comprising trisodium phosphate to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 11
Dependent Claim
15 words
The composition as set forth in claim 5, wherein the phosphate compound is sodium monofluorophosphate.
Claim 12
Dependent Claim
126 words
A composition for preventing and treating the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices by reducing the number of bacteria including Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in said orifices, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains stabilized chlorine dioxide in a concentration in the range of 0.005%-2.0% and a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate in a concentration of between 0.02%-3.0% to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 13
Dependent Claim
126 words
A composition for preventing and treating the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices by reducing the number of bacteria including Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in said orifices, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains stabilized chlorine dioxide in a concentration in the range of 0.005%-2.0% and a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate in a concentration of between 0.02%-3.0% to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 14
Dependent Claim
119 words
A composition for preventing and treating the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices by reducing the number of bacteria including Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in said orifices, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains at least 0.1% stabilized chlorine dioxide and at least 0.05% of a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 15
Dependent Claim
119 words
A composition for preventing and treating the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices by reducing the number of bacteria including Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in said orifices, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains at least 0.1% stabilized chlorine dioxide and at least 0.05% of a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 16
Dependent Claim
120 words
A composition for preventing and treating the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices by reducing the occurrence of leukoplakia in said orifices, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains stabilized chlorine dioxide in a concentration in the range of 0.005%-2.0% and a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate in a concentration of between 0.02%-3.0% to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 17
Dependent Claim
120 words
A composition for preventing and treating the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices by reducing the occurrence of leukoplakia in said orifices, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains stabilized chlorine dioxide in a concentration in the range of 0.005%-2.0% and a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate in a concentration of between 0.02%-3.0% to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 18
Dependent Claim
113 words
A composition for preventing and treating the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices by reducing the occurrence of leukoplakia in said orifices, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains at least 0.1% stabilized chlorine dioxide and at least 0.05% of a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 19
Dependent Claim
113 words
A composition for preventing and treating the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices by reducing the occurrence of leukoplakia in said orifices, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains at least 0.1% stabilized chlorine dioxide and at least 0.05% of a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 20
Dependent Claim
123 words
A composition for preventing and treating the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices by reducing the number of yeasts including Candida albicans in said orifices, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains stabilized chlorine dioxide in a concentration in the range of 0.005%-2.0% and a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate in a concentration of between 0.02%-3.0% to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 21
Dependent Claim
123 words
A composition for preventing and treating the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices by reducing the number of yeasts including Candida albicans in said orifices, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains stabilized chlorine dioxide in a concentration in the range of 0.005%-2.0% and a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate in a concentration of between 0.02%-3.0% to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 22
Dependent Claim
116 words
A composition for preventing and treating the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices by reducing the number of yeasts including Candida albicans in said orifices, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains at least 0.1% stabilized chlorine dioxide and at least 0.05% of a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
Claim 23
Dependent Claim
116 words
A composition for preventing and treating the epithelium of the rectal, vaginal, urethral, nasal, ocular, and auditory canal orifices by reducing the number of yeasts including Candida albicans in said orifices, said composition comprising a topical preparation selected from the group consisting of liquid solutions, suspensions, semi-solids, salves, creams, and suppositories, wherein the topical preparation contains at least 0.1% stabilized chlorine dioxide and at least 0.05% of a phosphate compound selected from the group consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate, or sodium monofluorophosphate to retard escape of chlorine dioxide from the composition at a pH in the range of 6.0 to 7.4, thereby increasing the shelf life and efficacy of the composition.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-02-05 | 1999-08-07 | 2000-02-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-02-05 | 2003-08-07 | 2004-02-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-02-05 | 2007-08-07 | 2008-02-06 | $7700.00 | Window Closed / Lapsed |